NEW YORK--(BUSINESS WIRE)--ClinConnect, a first-of-its-kind platform redefining how patients and clinical trials find each other, today announced a partnership with Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a multi-asset clinical stage disease-agnostic life science company providing an efficient model for compound development, to conduct a cocrystal development program to evaluate Conduit’s AZD1656 compound..

纽约-（BUSINESS WIRE）-重新定义患者和临床试验如何相互发现的首创平台ClinConnect今天宣布与Conduit Pharmaceuticals Inc.（纳斯达克股票代码：CDT）（“Conduit Pharmaceuticals”或“Conduit”），一家多资产临床阶段疾病不可知的生命科学公司，为化合物开发提供有效的模型，进行共晶开发计划以评估导管的AZD1656化合物。。

AZD1656 is a molecule with potential treatment applications currently in a wide variety of autoimmune disorders. The cocrystal program will seek to identify, characterize, and validate suitable cocrystal partners for AZD1656 to solve for current challenges associated with solubility, stability, and bioavailability.

AZD1656是目前在多种自身免疫性疾病中具有潜在治疗应用的分子。共晶计划将寻求鉴定，表征和验证AZD1656的合适共晶伙伴，以解决与溶解度，稳定性和生物利用度相关的当前挑战。

Pharmaceutical cocrystals may improve vital physicochemical characteristics of a drug, including solubility, dissolution, bioavailability, and stability of pharmaceutical compounds, while maintaining its therapeutic activity..

药物共晶可以改善药物的重要物理化学特性，包括药物化合物的溶解度，溶出度，生物利用度和稳定性，同时保持其治疗活性。。

“This partnership is a significant milestone for ClinConnect and is directly in line with our mission to build the bridge between patients and the treatments they deserve access to,” said Robert Maxwell, Founder and Chief Executive Officer of ClinConnect. “We deploy a variety of tools, both for patient use and at the infrastructure level, to accelerate the process of finding care and getting patients access to life-saving innovations earlier.

ClinConnect的创始人兼首席执行官罗伯特·麦克斯韦尔（Robert Maxwell）说：“这种合作关系是ClinConnect的重要里程碑，直接符合我们在患者与他们应获得的治疗之间架起桥梁的使命。“我们在患者使用和基础设施层面部署各种工具，以加快寻找护理的过程，并使患者更早获得挽救生命的创新。

Our collaboration with Conduit to advance this promising compound is an excellent example of how we can plug in to streamline and advance research, advocate for the patient, and solve problems.”.

我们与管道合作推进这一有前途的化合物是我们如何插入简化和推进研究，倡导患者和解决问题的一个很好的例子。

ClinConnect was founded with a philosophy to ensure patients have better access to the care they deserve. Starting with a flagship platform that provides a flourishing community for patients and their healthcare teams, ClinConnect offers an easy-to-navigate, real-time map of every trial known to the FDA that proactively matches patients to relevant studies.

ClinConnect的成立理念是确保患者更好地获得他们应有的护理。从为患者及其医疗团队提供蓬勃发展的社区的旗舰平台开始，ClinConnect提供FDA已知的每个试验的易于导航的实时地图，可主动将患者与相关研究相匹配。

The company also works directly with industry through its innovative and patient-centric trial design, regulatory navigation, and connection with all stakeholders across the healthcare continuum to drive faster drug development and medical innovation, ultimately working through all possible avenues to connect patients with treatments that could save lives..

该公司还通过创新和以患者为中心的试验设计，监管导航以及与整个医疗保健连续体中所有利益相关者的联系，直接与行业合作，推动更快的药物开发和医疗创新，最终通过所有可能的途径将患者与治疗联系起来这可以挽救生命。。

“Working with ClinConnect to develop this cocrystal program and advance AZD1656 was a natural fit. Together, we hope to move this compound forward faster than through traditional channels and with the same scientific rigor,” said Dr. Dave Tapolczay, Chief Executive Officer of Conduit. “AZD1656 has shown promise in early studies already conducted by AstraZeneca, and we are thrilled at its potential.”.

“与ClinConnect合作开发这个共晶项目，推进AZD1656是一个自然的选择，我们希望通过传统渠道和同样的科学严谨性，更快地推动这一化合物的发展，”管道首席执行官Dave Tapolczay博士说。“AZD1656在阿斯利康已经进行的早期研究中显示出了希望，我们对其潜力感到兴奋。”。

About ClinConnect

关于ClinConnect

ClinConnect is a technology company redefining how patients and clinical trials find each other. The company’s platform, an easy-to-navigate, real-time map of every trial known to the FDA, proactively matches patients and their care teams to relevant studies across the U.S. By breaking down the barriers many face when fighting disease, ClinConnect increases the probability of finding life changing clinical trials, notifying those eligible, and helping them through the application process.

ClinConnect是一家技术公司，重新定义患者和临床试验如何相互发现。该公司的平台是FDA已知的每项试验的易于导航的实时地图，可主动将患者及其护理团队与美国各地的相关研究相匹配。通过打破抗击疾病时许多面临的障碍，ClinConnect增加了寻找改变生命的临床试验，通知符合条件的临床试验，并帮助他们通过申请流程。

ClinConnect aims to ensure patients have better access to the care they deserve, to accelerate clinical trial enrollment from months to days, and to enable faster drug development and medical innovation. To learn more visit https://clinconnect.io/..

ClinConnect旨在确保患者能够更好地获得应有的护理，从几个月到几天加速临床试验注册，并加快药物开发和医疗创新。学习更多访问https://clinconnect.io/..

About Conduit Pharmaceuticals

关于Conduit Pharmaceuticals

Conduit is a disease-agnostic life science company providing an efficient model for compound development. Conduit is a departure from the traditional pharma/biotech business model whereby, typically, companies shepherd their assets through regulatory approval. Conduit acquires Phase II-ready assets and then seeks an exit through third-party license deals following successful clinical trials.

Conduit是一家与疾病无关的生命科学公司，为化合物开发提供了有效的模型。Conduit背离了传统的制药/生物技术业务模式，通常情况下，公司通过监管部门的批准来评估其资产。Conduit收购第二阶段就绪资产，然后在成功进行临床试验后通过第三方许可交易寻求退出。

Conduit is led by a highly experienced team of pharmaceutical executives, including Dr. David Tapolczay and Dr. Freda Lewis-Hall, and was established to fund the development of clinical molecules licensed from major pharmaceutical companies..

Conduit由一支经验丰富的制药高管团队领导，其中包括David Tapolczay博士和Freda Lewis Hall博士，并成立以资助主要制药公司许可的临床分子的开发。。